Children as Experimental Subjects: The High Court Clears the PATHWAYS Puberty-Blocker Trial

The High Court has refused an attempt to halt the NHS-backed PATHWAYS trial, allowing recruitment of children as young as eleven to begin. The ruling settles a question of judicial review. It does not establish that puberty blockers are safe, beneficial or ethically suitable for experimentation upon children. Indeed, the history of the policy raises the opposite question: why are drugs withdrawn from ordinary treatment because their safety and benefit are insufficiently established now to be administered experimentally to children in order to discover what they do?

On 31 July, the High Court refused permission for a judicial review challenging approval of the PATHWAYS puberty-blocker trial. Barring any successful further legal intervention, recruitment can therefore begin from 1 August. The proposed study will enrol up to 226 children under sixteen, with girls eligible from the age of eleven and boys from twelve. Half will receive puberty-suppressing drugs immediately; the remainder will begin them after a twelve-month delay.¹

That decision needs to be understood for what it is. The court has not pronounced puberty blockers safe. It has not determined that their administration to children suffering gender distress is beneficial. Nor has it resolved the ethical question of whether children ought to be subjected to this experiment. The proceedings concerned whether the regulatory decisions authorising the trial were legally open to challenge by judicial review.

Those distinctions matter because there will undoubtedly be an attempt to present the defeat of the legal challenge as another vindication of “the science”. It is no such thing.

The history preceding PATHWAYS is rather less reassuring.

In March 2024 NHS England removed puberty-suppressing hormones as a routine treatment for children with gender incongruence or gender dysphoria. Its present policy remains explicit: puberty suppressants are not available as a routine commissioning treatment option. NHS England explains why. The evidence concerning their “safety, risks, benefits and outcomes” is limited.²

The Government subsequently made restrictions on their private supply permanent. When Wes Streeting defended that decision in Parliament, he was unusually candid about what the Cass Review had uncovered: children had been prescribed puberty blockers without sufficient evidence that doing so was either safe or beneficial.³

One might have expected that conclusion to inaugurate a period of therapeutic caution.

Instead, it inaugurated an experiment.

PATHWAYS was devised following Dame Hilary Cass’s recommendation that further research should be undertaken. Its defenders therefore present the trial as the responsible answer to uncertainty: we do not know enough, they argue, and a controlled study is required in order to know more.

That proposition sounds reasonable until one remembers who is being asked to bear the uncertainty.

They are children.

The distinction is morally decisive. Scientific ignorance may create a reason for investigation, but it does not automatically create an ethical entitlement to expose a child to the intervention about which one is ignorant. Before experimental medicine can properly be administered to minors, the prospective knowledge gained cannot simply be placed on one side of the balance and the unknown consequences to the child on the other.

The child is not raw material for the production of evidence.

This problem became starker in February. The Medicines and Healthcare products Regulatory Agency, which had previously approved the trial, intervened and halted preparations after raising new concerns relating directly to the wellbeing of participants. The Department of Health and Social Care declared at the time that PATHWAYS would proceed only if expert evidence established that it was “both safe and necessary”.⁴

The MHRA’s concerns were not trifling. Subsequent regulatory documents required strengthened safeguards relating to bone health, cognition and vaginal bleeding, together with fuller information about fertility preservation. The revised trial also introduced minimum ages for participation.⁵ Contemporary reporting of the regulator’s correspondence described concern about potentially significant and as yet unquantified long-term biological harms.⁶

The trial was nevertheless reauthorised in June.

Perhaps the most remarkable feature of that reversal was the explanation from the researchers themselves. King’s College London said that the questions raised in February had not resulted from the emergence of new scientific evidence and that there were “no major changes to the design or conduct” of the trial.⁷

That ought to trouble anyone who remembers February’s standard.

The Government had said the study would proceed only if the evidence established that it was safe and necessary. Yet the concerns were subsequently resolved substantially through altered safeguards, monitoring, age limits and information given to participants rather than through some decisive new body of evidence demonstrating that the treatment itself had suddenly become safe.

The language of safeguards can obscure what those safeguards reveal.

If bone density must be repeatedly monitored because treatment may interfere with bone development, this tells us something about the intervention. If cognition requires special monitoring during a period of rapid neurological development, that too tells us something. If fertility preservation must be discussed with children and their parents before treatment, this is hardly incidental paperwork.

These are not precautions surrounding an aspirin.

They arise because puberty is not an illness. It is a fundamental stage of human development, involving the maturation of the reproductive system, skeleton, brain and secondary sexual characteristics. Puberty-suppressing drugs deliberately interrupt that process.

There are legitimate medical circumstances in which GnRH analogues are used, including precocious puberty. That fact is frequently invoked in defence of their use for gender-distressed children, but the analogy is misleading if stretched too far. A drug may have an established risk-benefit profile when used to treat pathological early puberty and an entirely different one when used to suppress normally timed puberty in a physically healthy child for psychological reasons. Medical indication is not a technicality. It determines why a risk may reasonably be incurred.

PATHWAYS itself acknowledges the uncertainty. King’s College London states that doctors and researchers do not yet know sufficiently what the benefits or risks are when puberty suppression is used for gender incongruence. It specifically identifies possible effects upon brain and bone development and says that there is insufficient research to determine whether such changes occur, their extent, or whether they reverse after treatment ceases.⁸

That admission cannot simultaneously be treated as a reason for withdrawing routine treatment and as though it posed no profound ethical difficulty when the same drugs are placed in the bodies of eleven- and twelve-year-olds under the title of research.

Nor does parental permission dissolve the problem.

Government ministers have themselves acknowledged in Parliament that the children cannot consent to participation in the legal sense relied upon for the trial; parental consent is required together with the child’s assent.³ Yet parents cannot consent away objective dangers on behalf of their children simply because they sincerely believe an intervention may help them. Parental authority exists for the protection of the child’s welfare. It does not turn an intervention of uncertain benefit and potentially serious developmental consequence into something ethically neutral.

The vulnerability of these children requires greater caution, not less.

Children presenting to gender services may also be experiencing autism, anxiety, depression, family difficulties, trauma, questions about sexuality or profound discomfort with the bodily changes of adolescence. The Cass Review’s great service was to insist that such children must be considered as whole human beings rather than hurried along a narrow medical pathway.

There is therefore something deeply unsettling about the language of “choice” when applied here. An eleven-year-old distressed by the approach of puberty cannot possess an adult understanding of fertility, sexual function, skeletal development, neurological maturation and the possibility that her present understanding of herself may change. A child may assent to stopping the frightening thing that is happening next month. That is not the same thing as comprehending what it may mean to interrupt a developmental process whose significance may not become apparent until years later.

The High Court’s decision does not answer any of this.

Courts reviewing administrative decisions are not substitutes for doctors, research ethics committees or moral reasoning. The fact that a judge concludes that regulatory authorities acted within the range of decisions lawfully open to them does not confer moral infallibility upon those authorities. Judicial review asks whether a decision was lawfully reached. It does not turn the decision into truth.

There is an uncomfortable precedent here from the opposite direction. In 2024 the High Court upheld restrictions on puberty blockers after the Secretary of State concluded that emergency action was necessary to avoid serious danger to health. Mrs Justice Lang held that the Government had been entitled to rely upon the Cass Review and the response of NHS England and other clinical bodies.⁹ Two years later another court has declined to prevent the same class of drugs being administered within an experiment.

The law can accommodate both decisions because the legal questions differ.

Parents may reasonably wonder whether the moral logic can.

The case for PATHWAYS ultimately depends upon an inversion which should be stated plainly. We lack sufficient evidence about whether puberty blockers are safe and beneficial for gender-distressed children. Because we lack that evidence, they cannot ordinarily be prescribed. Because they cannot ordinarily be prescribed, children will now be recruited into an experiment in which the drugs will be administered in order to acquire the evidence we lack.

For Nuntiatoria, that is a boundary which should not be crossed.

A civilised society does not owe medical researchers every experiment capable of answering an unresolved scientific question. Some knowledge may be desirable while the means proposed for obtaining it remain morally disproportionate. The first duty towards a vulnerable child is not to settle a controversy for future clinicians. It is to protect the child standing before us now.

There are other things that can be studied. Children experiencing gender distress can be followed longitudinally. Psychological and psychiatric treatments can be evaluated. Natural developmental outcomes can be recorded. The very extensive PATHWAYS HORIZON programme is already intended to gather observational evidence from thousands of young people attending NHS gender services.¹⁰ None of that requires pretending that the administration of puberty blockers to children becomes morally unproblematic because the word experimental has been printed across the protocol.

If anything, that word should make us more cautious.

The scandal exposed by Cass was that medicine moved ahead of evidence. The appropriate response cannot be to put another cohort of children between medicine and the evidence it seeks.

Tomorrow’s participants will not be abstractions in a dataset. They will be eleven-, twelve-, thirteen-, fourteen- and fifteen-year-old children living through the only puberty they will ever have.

They should not be the experiment.

Health Research Authority, PATHWAYS-HORIZON. The observational programme anticipates approximately 3,600 participants followed longitudinally.
Health Research Authority, PATHWAYS TRIAL, research summary, IRAS 1011645; King’s College London, PATHWAYS TRIAL. The HRA states that the study anticipates 226 participants under sixteen, randomised to immediate treatment or treatment after twelve months.
NHS England, Clinical policy: puberty suppressing hormones, 12 March 2024; NHS England, Children and young people’s gender services: implementing the Cass Review recommendations. NHS England states that routine prescribing was ended because of limited evidence concerning safety, risks, benefits and outcomes.
UK Parliament, House of Lords, Puberty Suppressants Trial, 18 December 2025. Ministers stated that children could not themselves consent to the trial, requiring parental consent and the young person’s assent, and described the earlier evidence for safe or beneficial prescribing as insufficient.
Department of Health and Social Care, PATHWAYS clinical trial paused following new MHRA advice, 20 February 2026.
Medicines and Healthcare products Regulatory Agency, Update on the PATHWAYS clinical trial, 19 June 2026; Health Research Authority, An update on the PATHWAYS TRIAL, 19 June 2026.
The Times, NHS puberty blocker trial to go ahead for children as young as 11, 19 June 2026; Open Justice with Tribunal Tweets, background to the July 2026 permission hearing.
King’s College London statement reported in The Times, 19 June 2026, concerning the revised PATHWAYS protocol.

King’s College London, PATHWAYS TRIAL and PATHWAYS CONNECT, current project documentation.

R (TransActual CIC and another) v Secretary of State for Health and Social Care and another [2024] EWHC 1936 (Admin); subsequent legal report summarising the judgment.

When “Catholic” Ceases to Qualify: Leo XIV, Freemasonry and the First Jewish President of the Catholic Biblical Association

August 18, 2026

Latest articles

Today’s homily: Wednesday Michaelmas Ember
The homily reflects on the significance of fasting and prayer in the Christian faith, emphasising their role in spiritual growth and self-mastery. By juxtaposing scripture from Amos and the Gospel of Mark, it highlights the need for gratitude and humility during abundance, urging believers to recognise their dependence on God. True repentance transforms and restores one’s relationship with Him.
Today’s Mass: September 16 Wednesday Michaelmas Ember
The post commemorates the Ember Days, originally aligned with Roman agricultural festivals. The Catholic Church adopted these days early in its history to honour true worship and avoid disrupting Roman converts’ practices. The Ember Days promote fasting, prayer, and gratitude towards God for nature’s gifts while assisting the needy.
SEPTEMBER EMBERTIDE
The September Ember Days, rooted in ancient Roman liturgy, are a time of reflection, fasting, and thanksgiving, coinciding with the autumn harvest. Marked by communal penance and prayers for clergy sanctification, these observances connect biblical themes of creation and sacrifice, urging Christians to evaluate their spiritual fruitfulness.
Today’s homily: Seven Sorrows of the Blessed Virgin Mary
On the Feast of the Seven Sorrows, the Church contemplates not merely Mary’s grief but her fidelity beneath the Cross. Through the liturgy, St Bernard, St John Damascene and St Thomas Aquinas, the homily shows that Christian resignation does not mean calling suffering good, but remaining faithful to God when suffering cannot be removed or understood. Mary’s stabat becomes the model of a faith which the sword can pierce, but cannot conquer.
Today’s Mass: September 15 The Seven Sorrows of the Blessed Virgin Mary
The Feast of the Exaltation of the Holy Cross, celebrated on September 14, commemorates the historical finding of the True Cross by Saint Helena, the dedication of churches by Constantine, and its restoration by Heraclius II. It honours the cross as the symbol of salvation, transforming a method of execution into a source of life and hope.